Alzheimer's disease drug development pipeline: 2023
Jeffrey L. Cummings(University of California, Los Angeles), Feixiong Cheng(Cleveland Clinic Lerner College of Medicine)
Alzheimer s & Dementia Translational Research & Clinical Interventions
April 1, 2023
Cited by 457
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818
On the path to 2025: understanding the Alzheimer’s disease continuum
|Alzheimer s Research & Therapy|2017|559